Hospitals
Physicians
Clinical trials
Contact us
Links
National Cancer Institute - Community Clinical Oncology Program

 

CURRENTLY OPEN CLINICAL TRIALS

Dayton Clinical Oncology Program accesses clinical trials through its membership in cooperative research groups funded by the National Cancer Institute (NCI), and through the pharmaceutical industry.

For a listing of research groups and links to their web sites, go to the "Links to Other Sites" tab at the left.

Clinical Trial By Disease Site
(Click the links to advance to a specific section)

   


General Cancer Control Trials for Symptom Management

A221301

Olanzapine For The Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial

URCC-10055

Assessment Of Cognitive Function In Breast Cancer And Lymphoma Patients Receiving Chemotherapy At Pre-Treatment, Post-Treatment And At Six Month Follow-Up

Information and Referral Form
URCC-12107

Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials

URCC-13059

Gap 70 + ;  A Geriatric Assessment Intervention For Patients Aged 70 And Over Receiving Chemotherapy For Advanced Cancer: Reducing Chemotherapy Toxicity In Older Adults 

URCC-13070

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

Back to top

BRAIN

TREATMENT:

N1174

Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme

RTOG-1205

Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone As Treatment for Recurrent Glioblastoma

Back to list

BREAST

BREAST CANCER CONTROL:

A011104

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

A221102

Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias

E1Z11

Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NSABP B-43

Herceptin Given Concurrently with Radiation Therapy vs Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

S1202

Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

Back to list

HER2-

A011106

ALTernate approaches for Clinical Stage II or III Estrogen Receptor positive breast cancer Neo Adjuvant TrEatment (ALTERNATE) in postmenopausel women:

NSABP B-55

Study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

S1207

Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

HER2+:

NSABP B-52

Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

METASTATIC:

E2108

The Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

Nodal:

A011202

Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

NSABP B-47

Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

NSABP B-51

Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

S1007

Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

Other:

E2112

Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

S1222

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor Positive Stage IV Breast Cancer

Back to list

GASTROINTESTINAL:

COLORECTAL CANCER PREVENTION:

OCCPI

Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

S0820

Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Billiary:

S1310

Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer.

COLORECTAL TREATMENT:

CALGB-80702

6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

E7208

Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

ESOPHAGEAL:

RTOG-1010

Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma

S1201

Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer

PANCREATIC:

E2211

Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumor

E2212

Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver

RECTAL:

N1048

Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Back to list

GENITOURINARY:

PROSTATE:

S1216

Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

RENAL:

A031203

Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

S0931

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy

Back to list

GYN:

GYN Cancer Control:

GOG-0244

The Lymphedema And Gynecologic Cancer (Leg) Study: Incidence, Risk Factors, And Impact In Newly Diagnosed Patients

patient eligibility summary

Cervical:

GOG-0263

Trial Of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy

GOG-0274

Trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

Endometrial:

GOG-0286B

Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA, Stage IVB, or Recurrent Endometrial Cancer

Ovarian:

GOG-0213

Trial Of Carboplatin And Paclitaxel (Or Gemcitabine) Alone Or In Combination With Bevacizumab (Nsc #704865, Ind #113912) Followed By Bevacizumab And Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary And Fallopian Tube Cancer. Nci-Supplied Agents: Bevacizumab

Uterine:

GOG-277

Trial Of Gemcitabine (Nsc# 613327) Plus Docetaxel (Nsc# 628503) Followed By Doxorubicin (Nsc# 123127) Versus Observation For Uterus-Limited, High-Grade Uterine Leiomyosarcoma

HEAD and NECK

NGR-HN001

Study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

LEUKEMIA:

AML:

E2906

Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)

S1203

Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)

CLL:

A041202

Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

E1912

Study of Ibrutinib (PCI- 32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)


ALL:

E1910

Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

LUNG:

NSCLC:

A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081105 (ALCHEMIST)

Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGRF) Mutant Non-Small Cell Lung Cancer (NSCLC)

E4512 (ALCHEMIST)

Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

E5508

Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paxlitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

NRG-LU001

Trial Of Concurrent Chemoradiotherapy +/- Metformin HCL In Locally Advanced NSCLC

RTOG-1306

Study Of Individualized Combined Modality Therapy For Stage III Non-Small Cell Lung Cancer(NSCLC)

S0819 Temporarily closed to accrual

Carboplatin/Taxol or Carboplatin/Taxol/Avastin with/without Concurrent Erbitux in Patients with Advanced Non-Small Cell Lung Cancer.

S1300

Trial Of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy In ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy

S1400

Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

SCLC:

E2511

Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

RTOG-0937

Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

LYMPHOMA:

CALGB-51101

Trial Of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy For Newly Diagnosed Primary CNS B-Cell Lymphoma

CALGB-50801

Trial Of Response-Adapted Therapy Based On Positron Emission Tomography (Pet) For Bulky Stage I And Stage II Classical Hodgkin Lymphoma (Hl)

E1411

Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)

E1412

Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Back to list

MELANOMA:

S1320

Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) And Trametinib (NSC-763093) In BRAF V600E/K Mutant Melanoma

 

MYELOMA:

E1A11

Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma

S1304

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease

SARCOMA:

ARST1321 Adult Only (≥18yr)

Pazopanib Neoadjuvant Trial in Non- Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Back to list

OTHER:

A021202

Pazopanib (NSC #737754, IND #75648) Versus Placebo in Patients With Progressive Carcinoid Tumors

A091105

A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)

N0392

Assessment of Patient Satisfaction with Participation on Phase II/III NCCTG Clinical Trials.

 

QUESTIONS?

CONTACT DAYTON CLINICAL ONCOLOGY PROGRAM
OR ASK YOUR PHYSICIAN
"Is There a Clinical Trial For Me?"

Contact Us

By Phone:
(937) 775-1350
Fax:
(937) 775-1358
By Mail:
Dayton Clinical Oncology Program
3123 Research Blvd., Suite 150
Dayton, Ohio 45420